Hemopressin (human, mouse)

Product Name:Hemopressin (human, mouse)

CAS No:1314035-51-2

Purity:95%

Molar Mass:1054.26

Chemical Formula:C50H79N13O12

Storage:Store at -20 degrees Celsius

Sequence:PVNFKLLSH

Target:endopeptidase 24.15

Application:

Hemopressin is a peptide that acts as an antagonist of the cannabinoid CB1 receptor. It is derived from the ??-chain of hemoglobin and functions to modulate cannabinoid receptor activity. In both human and mouse models, hemopressin is used to explore its effects on cannabinoid signaling, which influences pain perception, appetite, and mood regulation. By blocking the CB1 receptor, hemopressin helps researchers study the receptor's role in various physiological processes and its potential therapeutic applications in managing conditions such as chronic pain, obesity, and mood disorders. Its study in different species aids in understanding its broader physiological and therapeutic relevance.

Current Research:

Hemopressin, a nonapeptide derived from the α-chain of hemoglobin, has emerged as a significant subject of research in neuroscience and pharmacology due to its unique role as an endogenous modulator of cannabinoid receptors. Found in human and mouse models, hemopressin acts primarily as an inverse agonist of the CB1 cannabinoid receptor, offering a non-cannabinoid pathway to modulate this receptor's activity.

Neurological and Behavioral Effects
Research highlights the neuropharmacological potential of hemopressin in regulating pain and appetite. In rodent models, it has been shown to produce antinociceptive effects, reducing pain sensitivity without the psychoactive side effects commonly associated with traditional CB1 agonists. Additionally, hemopressin suppresses food intake by modulating hypothalamic pathways, suggesting its utility as a therapeutic target in obesity and metabolic syndrome.

Cardiovascular Implications
Beyond its effects on the central nervous system, hemopressin has been implicated in cardiovascular regulation. Studies in mice indicate that it influences blood pressure and vascular tone through its interaction with CB1 receptors in peripheral tissues. This opens possibilities for its application in managing conditions like hypertension.

Emerging Areas of Research
Hemopressin’s interaction with cannabinoid receptors extends to neurodegenerative diseases and mood disorders. Preliminary studies suggest its potential to mitigate neuroinflammation and neuronal damage, positioning it as a candidate for conditions like Alzheimer’s disease and depression. Furthermore, researchers are investigating the existence of hemopressin-derived peptides, such as RVD-Hemopressin, which may exhibit distinct or complementary pharmacological profiles.

Future Directions
Advancements in peptide engineering aim to enhance hemopressin’s stability and bioavailability, crucial steps for its translation into therapeutic applications. Research into its exact mechanisms and potential receptor-specific analogs is ongoing, promising a broader understanding of its physiological and pathological roles.

Reference:

Heimann, A. S., Dale, C. S., Guimarães, F. S., Reis, R. A., Navon, A., Shmuelov, M. A., … & Ferro, E. S. (2021). Hemopressin as a breakthrough for the cannabinoid field. Neuropharmacology, 183, 108406.